Endologix (ELGX) Shares Down 5.4%

Endologix, Inc. (NASDAQ:ELGX) fell 5.4% during trading on Monday . The stock traded as low as $2.66 and last traded at $2.83. 27,582 shares traded hands during mid-day trading, a decline of 91% from the average session volume of 309,267 shares. The stock had previously closed at $2.99.

Several brokerages recently commented on ELGX. ValuEngine upgraded shares of Endologix from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. BidaskClub upgraded shares of Endologix from a “buy” rating to a “strong-buy” rating in a research report on Thursday, May 24th. Stifel Nicolaus increased their target price on shares of Endologix from $4.50 to $5.00 and gave the stock a “hold” rating in a research report on Monday, May 21st. Piper Jaffray Companies downgraded shares of Endologix from an “overweight” rating to a “neutral” rating in a research report on Friday, August 10th. Finally, Zacks Investment Research upgraded shares of Endologix from a “sell” rating to a “hold” rating in a research report on Monday, May 7th. One investment analyst has rated the stock with a sell rating and nine have issued a hold rating to the company’s stock. Endologix presently has an average rating of “Hold” and an average target price of $4.00.

The company has a current ratio of 1.90, a quick ratio of 1.20 and a debt-to-equity ratio of 5.37. The stock has a market capitalization of $253.27 million, a PE ratio of -5.06 and a beta of 0.23.



Endologix (NASDAQ:ELGX) last released its earnings results on Thursday, August 9th. The medical instruments supplier reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.18). Endologix had a negative net margin of 40.92% and a negative return on equity of 69.06%. The company had revenue of $44.70 million during the quarter, compared to the consensus estimate of $44.43 million. During the same quarter in the prior year, the firm earned ($0.10) EPS. The company’s revenue was down 8.0% compared to the same quarter last year. sell-side analysts expect that Endologix, Inc. will post -0.7 earnings per share for the current year.

A number of large investors have recently bought and sold shares of ELGX. MetLife Investment Advisors LLC acquired a new position in Endologix in the 4th quarter valued at $236,000. Engineers Gate Manager LP acquired a new position in Endologix in the 2nd quarter valued at $442,000. Deutsche Bank AG grew its stake in Endologix by 111.7% in the 4th quarter. Deutsche Bank AG now owns 190,868 shares of the medical instruments supplier’s stock valued at $1,019,000 after buying an additional 100,703 shares during the last quarter. Schwab Charles Investment Management Inc. grew its stake in Endologix by 8.7% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 380,648 shares of the medical instruments supplier’s stock valued at $1,611,000 after buying an additional 30,585 shares during the last quarter. Finally, C WorldWide Group Holding A S grew its stake in Endologix by 22.3% in the 2nd quarter. C WorldWide Group Holding A S now owns 364,464 shares of the medical instruments supplier’s stock valued at $2,063,000 after buying an additional 66,486 shares during the last quarter. Institutional investors and hedge funds own 97.96% of the company’s stock.

Endologix Company Profile (NASDAQ:ELGX)

Endologix, Inc develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system.

Read More: Understanding Analyst Ratings

Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply